Search results for "Ulcer"

showing 10 items of 523 documents

Comment to “Management of cytomegalovirus infection in inflammatory bowel diseases”

2012

.

cytomegaloviruHepatologybusiness.industryGastroenterologyInflammatory Bowel DiseasesAntiviral AgentsInflammatory bowel diseaseCytomegalovirus infectionCrohn DiseaseCytomegalovirus InfectionsImmunologyHumansMedicineColitis Ulcerativecytomegalovirus; Inflammatory bowel diseasebusinessGanciclovircytomegalovirusImmunosuppressive AgentsDigestive and Liver Disease
researchProduct

HLA antigens in ulcerative colitis: a study in the Sicilian population

2008

HLA antigens were investigated in 41 Sicilian patients with ulcerative colitis and in 151 healthy controls. Frequencies of HLA-B5 and DR2 were increased in the group of patients with ulcerative colitis whereas the DR3 antigen frequency was decreased. However the corrected p values were not significant. Thus, present results indicate that in ulcerative colitis HLA linked genetic factors play a marginal role, if any.

education.field_of_studybusiness.industryImmunologyPopulationGeneral MedicineHuman leukocyte antigenmedicine.diseaseBiochemistryUlcerative colitisGene FrequencyItalyAntigenHLA AntigensImmunologyGeneticsHumansImmunology and AllergyMedicineColitis UlcerativeeducationbusinessTissue Antigens
researchProduct

A Single-Center Experience on Below-The-Knee Endovascular Treatment in Diabetic Patients

2020

Diabetic ulceration of the foot is a major global medical, social and economic problem and is the most frequent end-point of diabetic complications. A retrospective analysis from February 2017 to May 2019 of diabetic patients presenting below-the-knee artery disease (PAD) was carried out. Only patients treated with endovascular techniques as first choice treatment were evaluated. Outcome measured was perioperative mortality and morbidity. Freedom from occlusion, secondary patency and amputation rate were all registered. Additional maneuvers including stenting or angioplasty with drug eluting balloon (DEB) were reported. A total of 167 (101 male/66 female) patients with a mean age of 71 year…

endovascular surgeryulcerballoon angioplastyArticlesSettore MED/22 - Chirurgia Vascolarediabetic foot
researchProduct

Adamantiades-Behçet disease : an enigmatic process with oral manifestations

2006

La enfermedad de Adamantiades-Behçet es una vasculitis multisistémica crónica, potencialmente capaz de afectar a cualquier órgano o sistema del cuerpo humano y en la que la aparición repetida de úlceras orales es una de sus principales expresiones clínicas. La EAB es una patología de carácter universal, con una prevalencia variable en función de la población estudiada y que muestra una curiosa distribución geográfica. A pesar de ser un proceso conocido desde la antigüedad, su etiopatogenia en la que probablemente se hayan implicados factores genéticos, microbiológicos e inmunológicos, continua siendo enigmática. Su amplio espectro de manifestaciones clínicas orales, genitales, cutáneas, ocu…

enfermedad de Behçetanimal structuresoral ulcersEnfermedad de Adamantiades-BehçetfungiUNESCO::CIENCIAS MÉDICASúlceras oralesAdamantiades-Behçet disease:CIENCIAS MÉDICAS [UNESCO]aftasBehçet diseaseaphthous stomatitisvasculitis
researchProduct

Owrzodzenie podudzia związane z niewydolnością żyły mięśnia brzuchatego łydki - opis przypadku

2008

Przedstawiono przypadek chorego z żylnymi owrzodzeniami goleni na tle niewydolności żyły mięśnia brzuchatego łydki z układem refleksowym typu „enigma of the gastrocnemius vein”. Operacja polegała na wybiórczym podwiązaniu niewydolnego perforatora łączącego żyłę mięśnia brzuchatego łydki z żyłą odstrzałkową. Po operacji owrzodzenia wygoiły się oraz ustąpił refluks w układzie żyły mięśnia brzuchatego łydki. Omówiono również taktykę operacji u chorych z żylakami towarzyszącymi niewydolności żyły mięśnia brzuchatego łydki.

gastrocnemius veinprzewlekła niewydolność żylnaowrzodzenia podudzichronic venous insufficiencyżyła mięśnia brzuchatego łydkileg ulcersPolski Przegląd Chirurgiczny
researchProduct

Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis

2020

Although most patients with ulcerative colitis should be given topical treatment, different studies have shown that they are underused in clinical practice. The purpose of this article is to answer 10 specific questions about which drugs are available for topical use in the treatment of ulcerative colitis, and their characteristics in terms of formulation, dosage, presentation, application and proximal distribution of rectal-administered drugs. The efficacy of available topical drugs and the benefits of combining different formulations and routes of administration, and their usefulness during disease remission are evaluated. Finally, a series of recommendations addressed to patients are giv…

glucocorticoidesmedicine.medical_specialtycolitisAdministration TopicalhumanosAnti-Inflammatory AgentsTopical treatmentmesalamina03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMesalazineTopical treatmentmedicineMesalazinaHumansCorticosteroidsMesalamineGlucocorticoidsCrohn's diseasebusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseantiinflamatoriosUlcerative colitisDermatologyClinical PracticechemistryUlcerative colitis030220 oncology & carcinogenesisDisease remission030211 gastroenterology & hepatologyColitis UlcerativeMesalazinebusiness
researchProduct

HLA-DQ de enfermedad celíaca en pacientes con enfermedad inflamatoria intestinal crónica

2015

Introducción: La enfermedad celíaca (EC) y la Enfermedad Inflamatoria Intestinal Crónica (EIIC, que incluye CU –colitis ulcerosa- y ECr –Enfermedad de Crohn-) son enfermedades cuya incidencia y prevalencia va en aumento, y en las que se consideraba que tener una de ellas aumentaba la predisposición a la otra. El HLA-DQ 2 y DQ8, de riesgo de EC (HLA-EC), tiene un alto valor predictivo negativo, estando presente en el 95-99% de los celíacos. Nuestra hipótesis era que el HLA-EC no es más frecuente en la EIIC. Material y método: Se incluyeron prospectivamente pacientes adultos con EIIC, de origen caucásico, de nuestra Unidad de EIIC. Se les realizaba entrevista, estudio de su historia clínica y…

hlaUNESCO::CIENCIAS MÉDICAS ::Medicina interna::Gastroenterologíaenfermedad de Crohn:CIENCIAS MÉDICAS ::Medicina interna::Gastroenterología [UNESCO]celiaquíacolitis ulcerosa
researchProduct

Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data

2022

Background: The COVID-19 outbreak has led IBD clinics to adopt a remote monitoring approach in order to guarantee an adequate follow-up of patients with inflammatory bowel disease (IBD) and ensure the rules of social distancing. Aim: The aim of the study was to perform a survey on IBD patients who underwent remote monitoring in our tertiary referral center, to assess adherence, patients’ perceptions and satisfaction, and finally their opinions for future monitoring. Furthermore, we evaluated changes in disease activity and Quality of Life (QoL) using validated questionnaires. Methods: Consecutive patients with IBD scheduled for follow-up visits were switched to remote monitoring throu…

inflammatory bowel disease; COVID-19; telemedicine; ulcerative colitis; Crohn’s DiseaseHepatologyinflammatory bowel diseaseGastroenterologyCrohn's Disease.COVID-19telemedicineulcerative coliti
researchProduct

Cyclosporine or infliximab as rescue therapy in severe 2 refractory ulcerative colitis: Early and long-term data 3 from a retrospective observational…

2012

Introduction: About 30–40% of patients with acute severe ulcerative colitis (UC) fail to respond 23 to intensive intravenous (iv) corticosteroid treatment. Iv cyclosporine and infliximab are an ef- 24 fective rescue therapy in steroid-refractory UC patients but up to now it is still unclear which is Q225 the best therapeutic choice in this setting of patients. 26 Methods: We reviewed our series of severe steroid-refractory colitis admitted consecutively in 27 our referral center since 1994 comparing two historical cohort treated with cyclosporine or 28 infliximab. Iv cyclosporine was administered at the dosage of 2 mg/kg and infliximab at the dos- 29 age of 5 mg/kg. The main outcome was the…

infliximabulcerative colitiscyclosporine
researchProduct

INFLIXIMAB FOR PEDIATRIC ULCERATIVE COLITIS:A RETROSPECTIVE ITALIAN MULTICENTER STUDY

2008

. Dig Liver Dis. 2008 Jul;40 Suppl 2:S260-4. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Cucchiara S, Romeo E, Viola F, Cottone M, Fontana M, Lombardi G, Rutigliano V, de'Angelis GL, Federici T. Division Pediatric Gastroenterology and Hepatology, Department of Pediatrics, University of Rome "La Sapienza", Rome, Italy. salvatore.cucchiara@uniroma1.it BACKGROUND: Infliximab (IFX), the chimeric anti TNFalpha antibody, an established treatment for Crohn's disease in adults and in children, is used less frequently in ulcerative colitis (UC). AIM OF THE STUDY: To report the clinical course of pediatric patients with active UC receiving IFX. PATIENTS AND…

infliximab.ulcerative colitis.
researchProduct